1. Bifulco M, Pisanti S. Medicinal use of cannabis in Europe: the fact that more countries legalize the medicinal use of cannabis should not become an argument for unfettered and uncontrolled use. EMBO Rep. 2015;16(2):130–2. doi:10.15252/embr.201439742.

2. Zimmerman AM, Zimmerman S, Raj AY. Effects of cannabinoids on spermatogenesis in mice. Adv Biosci. 1978;22–23:407–18.

3. Schuel H, Schuel R, Zimmerman AM, Zimmerman S. Cannabinoids reduce fertility of sea urchin sperm. Biochem Cell Biol. 1987;65(2):130–6.

4. Bari M, Battista N, Pirazzi V, Maccarrone M. The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci (Landmark Ed). 2011;16:498–516.

5. Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug use on male fertility. J Androl. 2012;33(4):515–28. doi:10.2164/jandrol.110.011874.

6. WHO. Management of substance abuse: facts and figures. WHO. 2015. http://www.who.int/substance_abuse/facts/cannabis/en/. Accessed 11 Feb 2015 2015

7. SAMHSA. National survey on drug use and health: summary of national findings. Department of Health and Human Services. 2013. http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.htm#ch2. Accessed 18 Feb 2015

8. Fasano S, Meccariello R, Cobellis G, Chianese R, Cacciola G, Chioccarelli T, et al. The endocannabinoid system: an ancient signaling involved in the control of male fertility. Ann N Y Acad Sci. 2009;1163:112–24. doi:10.1111/j.1749-6632.2009.04437.x.

9. Rossato M, Pagano C, Vettor R. The cannabinoid system and male reproductive functions. J Neuroendocrinol. 2008;20 Suppl 1:90–3. doi:10.1111/j.1365-2826.2008.01680.x.

10. Shamloul R, Bella AJ. Impact of cannabis use on male sexual health. J Sex Med. 2011;8(4):971–5. doi:10.1111/j.1743-6109.2010.02198.x.

11. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66(1):95–105. doi:10.1001/archgenpsychiatry.2008.519.

12. Grotenhermen F. Some practice-relevant aspects of the pharmacokinetics of THC. Forsch Komplementarmed. 1999;6 Suppl 3:37–9. doi:57155.

13. Thakur GA, Duclos Jr RI, Makriyannis A. Natural cannabinoids: templates for drug discovery. Life Sci. 2005;78(5):454–66. doi:10.1016/j.lfs.2005.09.014.

14. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003;2(5):291–8.

15. Sugiura T, Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids. 2000;108(1–2):89–106.

16. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.

17. Habayeb OM, Bell SC, Konje JC. Endogenous cannabinoids: metabolism and their role in reproduction. Life Sci. 2002;70(17):1963–77.

18. Meccariello R, Battista N. Updates in reproduction coming from the endocannabinoid system. Int J Endocrinol. 2014;2014:412354. doi:10.1155/2014/412354.

19. Cacciola G, Chioccarelli T, Ricci G, Meccariello R, Fasano S, Pierantoni R, et al. The endocannabinoid system in vertebrate male reproduction: a comparative overview. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S24–30. doi:10.1016/j.mce.2008.01.004.

20. Battista N, Rapino C, Di Tommaso M, Bari M, Pasquariello N, Maccarrone M. Regulation of male fertility by the endocannabinoid system. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S17–23. doi:10.1016/j.mce.2008.01.010.

21. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14(9):923–30. doi:10.1038/nm.f.1869.

22. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev. 2008;108(5):1687–707. doi:10.1021/cr0782067.

23. Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport. 2000;11(6):1231–5.

24. Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Phil Trans R Soc Lond Ser B Biol Sci. 2012;367(1607):3216–28. doi:10.1098/rstb.2011.0382.

25. Ligresti A, Cascio MG, Di Marzo V. Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Disord. 2005;4(6):615–23.

26. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther. 2007;114(1):13–33. doi:10.1016/j.pharmthera.2007.01.005.

27. Lewis SE, Maccarrone M. Endocannabinoids, sperm biology and human fertility. Pharmacol Res. 2009;60(2):126–31. doi:10.1016/j.phrs.2009.02.009.

28. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem. 2005;74:411–32. doi:10.1146/annurev.biochem.74.082803.133450.

29. Di Marzo V. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci. 1999;65(6–7):645–55.

30. Di Marzo V, De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem. 2010;17(14):1430–49.

31. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161–202.

32. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5. doi:10.1038/365061a0.

33. Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 1986;29(3):307–13.

34. Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol. 1995;35:607–34. doi:10.1146/annurev.pa.35.040195.003135.

35. Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol. 1992;106(2):231–2.

36. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–4. doi:10.1038/346561a0.

37. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62(4):588–631. doi:10.1124/pr.110.003004.

38. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77(2):299–318.

39. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932–6.

40. El-Talatini MR, Taylor AH, Elson JC, Brown L, Davidson AC, Konje JC. Localisation and function of the endocannabinoid system in the human ovary. PLoS One. 2009;4(2), e4579. doi:10.1371/journal.pone.0004579.

41. Tambaro S, Mongeau R, Dessi C, Pani L, Ruiu S. Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors. Eur J Pharmacol. 2005;525(1–3):150–3. doi:10.1016/j.ejphar.2005.09.058.

42. Walczak JS, Price TJ, Cervero F. Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience. 2009;159(3):1154–63. doi:10.1016/j.neuroscience.2009.01.050.

43. Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol. 1993;327(4):535–50. doi:10.1002/cne.903270406.

44. Pertwee RG, Ross RA, Craib SJ, Thomas A. (−)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002;456(1–3):99–106.

45. Gye MC, Kang HH, Kang HJ. Expression of cannabinoid receptor 1 in mouse testes. Arch Androl. 2005;51(3):247–55.

46. Agirregoitia E, Carracedo A, Subiran N, Valdivia A, Agirregoitia N, Peralta L, et al. The CB(2) cannabinoid receptor regulates human sperm cell motility. Fertil Steril. 2010;93(5):1378–87. doi:10.1016/j.fertnstert.2009.01.153.

47. Rossato M, Ion Popa F, Ferigo M, Clari G, Foresta C. Human sperm express cannabinoid receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. J Clin Endocrinol Metab. 2005;90(2):984–91. doi:10.1210/jc.2004-1287.

48. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci Off J Soc Neurosci. 2009;29(14):4564–70. doi:10.1523/jneurosci.0786-09.2009.

49. Maccarrone M, Cecconi S, Rossi G, Battista N, Pauselli R, Finazzi-Agro A. Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse Sertoli cells. Endocrinology. 2003;144(1):20–8. doi:10.1210/en.2002-220544.

50. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008;105(7):2699–704. doi:10.1073/pnas.0711278105.

51. Moriconi A, Cerbara I, Maccarrone M, Topai A. GPR55: current knowledge and future perspectives of a purported “type-3” cannabinoid receptor. Curr Med Chem. 2010;17(14):1411–29.

52. Francavilla F, Battista N, Barbonetti A, Vassallo MR, Rapino C, Antonangelo C, et al. Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability. Endocrinology. 2009;150(10):4692–700. doi:10.1210/en.2009-0057.

53. Toth A, Blumberg PM, Boczan J. Anandamide and the vanilloid receptor (TRPV1). Vitam Horm. 2009;81:389–419. doi:10.1016/s0083-6729(09)81015-7.

54. Pistis M, Melis M. From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem. 2010;17(14):1450–67.

55. Shalet SM. Normal testicular function and spermatogenesis. Pediatr Blood Cancer. 2009;53(2):285–8. doi:10.1002/pbc.22000.

56. Wenger T, Ledent C, Csernus V, Gerendai I. The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Biochem Biophys Res Commun. 2001;284(2):363–8. doi:10.1006/bbrc.2001.4977.

57. Scorticati C, Fernandez-Solari J, De Laurentiis A, Mohn C, Prestifilippo JP, Lasaga M, et al. The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc Natl Acad Sci U S A. 2004;101(32):11891–6. doi:10.1073/pnas.0404366101.

58. Farkas I, Kallo I, Deli L, Vida B, Hrabovszky E, Fekete C, et al. Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. Endocrinology. 2010;151(12):5818–29. doi:10.1210/en.2010-0638.

59. Fernandez-Solari J, Scorticati C, Mohn C, De Laurentiis A, Billi S, Franchi A, et al. Alcohol inhibits luteinizing hormone-releasing hormone release by activating the endocannabinoid system. Proc Natl Acad Sci U S A. 2004;101(9):3264–8. doi:10.1073/pnas.0307346101.

60. Olah M, Milloh H, Wenger T. The role of endocannabinoids in the regulation of luteinizing hormone and prolactin release. Differences between the effects of AEA and 2AG. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S36–40. doi:10.1016/j.mce.2008.01.005.

61. Gonzalez S, Manzanares J, Berrendero F, Wenger T, Corchero J, Bisogno T, et al. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. Neuroendocrinology. 1999;70(2):137–45. doi:54468.

62. Rossi G, Gasperi V, Paro R, Barsacchi D, Cecconi S, Maccarrone M. Follicle-stimulating hormone activates fatty acid amide hydrolase by protein kinase A and aromatase-dependent pathways in mouse primary Sertoli cells. Endocrinology. 2007;148(3):1431–9. doi:10.1210/en.2006-0969.

63. McDonald CA, Millena AC, Reddy S, Finlay S, Vizcarra J, Khan SA, et al. Follicle-stimulating hormone-induced aromatase in immature rat Sertoli cells requires an active phosphatidylinositol 3-kinase pathway and is inhibited via the mitogen-activated protein kinase signaling pathway. Mol Endocrinol. 2006;20(3):608–18. doi:10.1210/me.2005-0245.

64. Aquila S, Guido C, Santoro A, Perrotta I, Laezza C, Bifulco M, et al. Human sperm anatomy: ultrastructural localization of the cannabinoid1 receptor and a potential role of anandamide in sperm survival and acrosome reaction. Anat Rec (Hoboken). 2010;293(2):298–309. doi:10.1002/ar.21042.

65. Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, Piomelli D, et al. N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids. 2002;121(1–2):211–27.

66. Amoako AA, Marczylo TH, Lam PM, Willets JM, Derry A, Elson J, et al. Quantitative analysis of anandamide and related acylethanolamides in human seminal plasma by ultra performance liquid chromatography tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878(31):3231–7. doi:10.1016/j.jchromb.2010.09.024.

67. Schuel H, Burkman LJ, Lippes J, Crickard K, Mahony MC, Giuffrida A, et al. Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Mol Reprod Dev. 2002;63(3):376–87. doi:10.1002/mrd.90021.

68. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004;279(7):5298–305. doi:10.1074/jbc.M306642200.

69. Amoako AA, Marczylo TH, Marczylo EL, Elson J, Willets JM, Taylor AH, et al. Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia. Hum Reprod. 2013;28(8):2058–66. doi:10.1093/humrep/det232.

70. Aquila S, Guido C, Santoro A, Gazzerro P, Laezza C, Baffa MF, et al. Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm. Br J Pharmacol. 2010;159(4):831–41. doi:10.1111/j.1476-5381.2009.00570.x.

71. Gervasi MG, Osycka-Salut C, Caballero J, Vazquez-Levin M, Pereyra E, Billi S, et al. Anandamide capacitates bull spermatozoa through CB1 and TRPV1 activation. PLoS One. 2011;6(2), e16993. doi:10.1371/journal.pone.0016993.

72. Bernabo N, Palestini P, Chiarini M, Maccarrone M, Mattioli M, Barboni B. Endocannabinoid-binding CB1 and TRPV1 receptors as modulators of sperm capacitation. Commun Integr Biol. 2012;5(1):68–70.

73. Cobellis G, Cacciola G, Scarpa D, Meccariello R, Chianese R, Franzoni MF, et al. Endocannabinoid system in frog and rodent testis: type-1 cannabinoid receptor and fatty acid amide hydrolase activity in male germ cells. Biol Reprod. 2006;75(1):82–9. doi:10.1095/biolreprod.106.051730.

74. Ricci G, Cacciola G, Altucci L, Meccariello R, Pierantoni R, Fasano S, et al. Endocannabinoid control of sperm motility: the role of epididymus. Gen Comp Endocrinol. 2007;153(1–3):320–2. doi:10.1016/j.ygcen.2007.02.003.

75. Maccarrone M, Barboni B, Paradisi A, Bernabo N, Gasperi V, Pistilli MG, et al. Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction. J Cell Sci. 2005;118(Pt 19):4393–404. doi:10.1242/jcs.02536.

76. Rossato M. Endocannabinoids, sperm functions and energy metabolism. Mol Cell Endocrinol. 2008;286(1–2 Suppl 1):S31–5. doi:10.1016/j.mce.2008.02.013.

77. Aquila S, Guido C, Laezza C, Santoro A, Pezzi V, Panza S, et al. A new role of anandamide in human sperm: focus on metabolism. J Cell Physiol. 2009;221(1):147–53. doi:10.1002/jcp.21837.

78. Pierantoni R, Cobellis G, Meccariello R, Cacciola G, Chianese R, Chioccarelli T, et al. CB1 activity in male reproduction: mammalian and nonmammalian animal models. Vitam Horm. 2009;81:367–87. doi:10.1016/s0083-6729(09)81014-5.

79. Rapino C, Battista N, Bari M, Maccarrone M. Endocannabinoids as biomarkers of human reproduction. Hum Reprod Update. 2014;20(4):501–16. doi:10.1093/humupd/dmu004.

80. Murphy LL, Munoz RM, Adrian BA, Villanua MA. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis. 1998;5(6 Pt B):432–46.

81. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1):73–100. doi:10.1210/er.2005-0009.

82. Wang H, Dey SK, Maccarrone M. Jekyll and hyde: two faces of cannabinoid signaling in male and female fertility. Endocr Rev. 2006;27(5):427–48. doi:10.1210/er.2006-0006.

83. Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. Pharmacol Biochem Behav. 1986;24(6):1749–54.

84. Vescovi PP, Pedrazzoni M, Michelini M, Maninetti L, Bernardelli F, Passeri M. Chronic effects of marihuana smoking on luteinizing hormone, follicle-stimulating hormone and prolactin levels in human males. Drug Alcohol Depend. 1992;30(1):59–63.

85. Kolodny RC, Masters WH, Kolodner RM, Toro G. Depression of plasma testosterone levels after chronic intensive marihuana use. N Engl J Med. 1974;290(16):872–4. doi:10.1056/nejm197404182901602.

86. Mendelson JH, Kuehnle J, Ellingboe J, Babor TF. Plasma testosterone levels before, during and after chronic marihuana smoking. N Engl J Med. 1974;291(20):1051–5. doi:10.1056/nejm197411142912003.

87. Hembree WC, Zeidenberg P, Nahas GG. Marihuana’s effects on human gonadal function. In: Nahas GG, editor. Marihuana, chemistry, biochemistry and cellular effects. New York: Springer; 1976. p. 521–32.

88. Huizink AC, Ferdinand RF, Ormel J, Verhulst FC. Hypothalamic-pituitary-adrenal axis activity and early onset of cannabis use. Addiction. 2006;101(11):1581–8. doi:10.1111/j.1360-0443.2006.01570.x.

89. Wenger T, Rettori V, Snyder GD, Dalterio S, McCann SM. Effects of delta-9-tetrahydrocannabinol on the hypothalamic-pituitary control of luteinizing hormone and follicle-stimulating hormone secretion in adult male rats. Neuroendocrinology. 1987;46(6):488–93.

90. Smith RG, Besch NF, Besch PK, Smith CG. Inhibition of gonadotropin by delta9-tetrahydrocannabinol:mediation by steroid receptors? Science. 1979;204(4390):325–7.

91. Wenger T, Fernandez-Ruiz JJ, Ramos JA. Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland. J Neuroendocrinol. 1999;11(11):873–8.

92. Friedrich G, Nepita W, Andre T. Serum testosterone concentrations in cannabis and opiate users. Beitr Gerichtl Med. 1990;48:57–66.

93. Smith CG, Moore CE, Besch NF, Besch PK. The effect of marihuana delta 9—tetrahydrocannabinol on the secretion of sex hormones in the mature male rhesus monkey. Clin Chem. 1976;22(7):1184.

94. List A, Nazar B, Nyquist S, Harclerode J. The effects of delta9-tetrahydrocannabinol and cannabidiol on the metabolism of gonadal steroids in the rat. Drug Metab Dispos. 1977;5(3):268–72.

95. Lee SY, Oh SM, Chung KH. Estrogenic effects of marijuana smoke condensate and cannabinoid compounds. Toxicol Appl Pharmacol. 2006;214(3):270–8. doi:10.1016/j.taap.2005.12.019.

96. Fujimoto GI, Morrill GA, O’Connell ME, Kostellow AB, Retura G. Effects of cannabinoids given orally and reduced appetite on the male rat reproductive system. Pharmacology. 1982;24(5):303–13.

97. Lacson JC, Carroll JD, Tuazon E, Castelao EJ, Bernstein L, Cortessis VK. Population-based case–control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer. 2012;118(21):5374–83. doi:10.1002/cncr.27554.

98. Harclerode J, Nyquist SE, Nazar B, Lowe D. Effects of cannabis on sex hormones and testicular enzymes of the rodent. Adv Biosci. 1978;22–23:395–405.

99. Yassa HA, Dawood Ael W, Shehata MM, Abdel-Hady RH, Aal KM. Subchronic toxicity of cannabis leaves on male albino rats. Hum Exp Toxicol. 2010;29(1):37–47. doi:10.1177/0960327109354312.

100. Mandal TK, Das NS. Testicular toxicity in cannabis extract treated mice: association with oxidative stress and role of antioxidant enzyme systems. Toxicol Ind Health. 2010;26(1):11–23. doi:10.1177/0748233709354553.

101. Dixit VP, Gupta CL, Agrawal M. Testicular degeneration and necrosis induced by chronic administration of cannabis extract in dogs. Endokrinologie. 1977;69(3):299–305.

102. Banerjee A, Singh A, Srivastava P, Turner H, Krishna A. Effects of chronic bhang (cannabis) administration on the reproductive system of male mice. Birth Defects Res B Dev Reprod Toxicol. 2011;92(3):195–205. doi:10.1002/bdrb.20295.

103. Chakravarty I, Ghosh JJ. Influence of cannabis and delta-9-tetrahydrocannabinol on the biochemistry of the male reproductive organs. Biochem Pharmacol. 1981;30(4):273–6.

104. Nahas GG, Frick HC, Lattimer JK, Latour C, Harvey D. Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa. Hum Psychopharmacol. 2002;17(2):103–13. doi:10.1002/hup.369.

105. Hembree 3rd WC, Nahas GG, Zeidenberg P, Huang HF. Changes in human spermatozoa associated with high dose marihuana smoking. Adv Biosci. 1978;22–23:429–39.

106. Pacey AA, Povey AC, Clyma JA, McNamee R, Moore HD, Baillie H, et al. Modifiable and non-modifiable risk factors for poor sperm morphology. Hum Reprod. 2014;29(8):1629–36. doi:10.1093/humrep/deu116.

107. Barbonetti A, Vassallo MR, Fortunato D, Francavilla S, Maccarrone M, Francavilla F. Energetic metabolism and human sperm motility: impact of CB(1) receptor activation. Endocrinology. 2010;151(12):5882–92. doi:10.1210/en.2010-0484.

108. Whan LB, West MC, McClure N, Lewis SE. Effects of delta-9-tetrahydrocannabinol, the primary psychoactive cannabinoid in marijuana, on human sperm function in vitro. Fertil Steril. 2006;85(3):653–60. doi:10.1016/j.fertnstert.2005.08.027.

109. Zimmerman AM, Bruce WR, Zimmerman S. Effects of cannabinoids on sperm morphology. Pharmacology. 1979;18(3):143–8.

110. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383–91. doi:10.1016/s0140-6736(09)61037-0.

111. Morgan DJ, Muller CH, Murataeva NA, Davis BJ, Mackie K. Delta9-Tetrahydrocannabinol (Delta9-THC) attenuates mouse sperm motility and male fecundity. Br J Pharmacol. 2012;165(8):2575–83. doi:10.1111/j.1476-5381.2011.01506.x.

112. Badawy ZS, Chohan KR, Whyte DA, Penefsky HS, Brown OM, Souid AK. Cannabinoids inhibit the respiration of human sperm. Fertil Steril. 2009;91(6):2471–6. doi:10.1016/j.fertnstert.2008.03.075.

113. Perez LE, Smith CG, Asch RH. Delta 9-tetrahydrocannabinol inhibits fructose utilization and motility in human, rhesus monkey, and rabbit sperm in vitro. Fertil Steril. 1981;35(6):703–5.

114. du Plessis SS, Agarwal A, Mohanty G, van der Linde M. Oxidative phosphorylation versus glycolysis: what fuel do spermatozoa use? Asian J Androl. 2014. doi:10.4103/1008-682x.135123.

115. Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol. 2005;76(1):1–21. doi:10.1016/j.pneurobio.2005.06.002.

116. Chowdhury AR. Effect of pharmacological agents on male reproduction. Adv Contracept Deliv Syst. 1987;3(4):347–52.

117. Abel EL. Marihuana and sex: a critical survey. Drug Alcohol Depend. 1981;8(1):1–22.

118. Chopra GS, Jandu BS. Psychoclinical effects of long-term marijuana use in 275 Indian chronic users. A comparative assessment of effects in Indian and USA users. Ann N Y Acad Sci. 1976;282:95–108.

119. Dhawan K, Sharma A. Restoration of chronic-delta 9-THC-induced decline in sexuality in male rats by a novel benzoflavone moiety from Passiflora incarnata Linn. Br J Pharmacol. 2003;138(1):117–20. doi:10.1038/sj.bjp.0705015.

120. Murphy LL, Gher J, Steger RW, Bartke A. Effects of delta 9-tetrahydrocannabinol on copulatory behavior and neuroendocrine responses of male rats to female conspecifics. Pharmacol Biochem Behav. 1994;48(4):1011–7.

121. Gorzalka BB, Hill MN, Chang SC. Male–female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. Horm Behav. 2010;58(1):91–9. doi:10.1016/j.yhbeh.2009.08.009.

122. Tart CT. Marijuana intoxication common experiences. Nature. 1970;226(5247):701–4.

123. Halikas J, Weller R, Morse C. Effects of regular marijuana use on sexual performance. J Psychoactive Drugs. 1982;14(1–2):59–70. doi:10.1080/02791072.1982.10471911.

124. Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol. 2005;168:147–85.

125. Mialon A, Berchtold A, Michaud PA, Gmel G, Suris JC. Sexual dysfunctions among young men: prevalence and associated factors. J Adolesc Health. 2012;51(1):25–31. doi:10.1016/j.jadohealth.2012.01.008.

126. Aversa A, Rossi F, Francomano D, Bruzziches R, Bertone C, Santiemma V, et al. Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. Int J Impot Res. 2008;20(6):566–73. doi:10.1038/ijir.2008.43.

127. Smith AM, Ferris JA, Simpson JM, Shelley J, Pitts MK, Richters J. Cannabis use and sexual health. J Sex Med. 2010;7(2 Pt 1):787–93. doi:10.1111/j.1743-6109.2009.01453.x.

128. Park B, McPartland JM, Glass M. Cannabis, cannabinoids and reproduction. Prostaglandins Leukot Essent Fat Acids. 2004;70(2):189–97.

129. Alvarez S. Do some addictions interfere with fertility? Fertil Steril. 2015;103(1):22–6. doi:10.1016/j.fertnstert.2014.11.008.